Logo

FDA approves combo of Opdivo plus Yervoy for advanced liver cancer

FDA approves combo of Opdivo plus Yervoy for advanced liver cancer

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC). The approval of Opdivo plus Yervoy was granted to Bristol Myers Squibb.

👉 Full Story